Can a nanovaccine be the solution to pancreatic cancer?

The most lethal cancer and with the worse prognosis in advanced stages is the pancreatic cancer. Therapies that are giving good results in other tumors (such as monoclonal antibodies anti-CTLA-4) are not effective in this type of cancer.
Nanovaccines are composed by small substances (nano), that could carry, either inside, or on their surface, elements called antigens. 
In the MINECO project lead by Prof. África González, the researchers will use nanoparticles loaded with antigens from tumor cells to induce the immune response against pancreatic cancer cells. 

 

Read more in:

DUVI UVigo

GCiencia